SCHEMBL24469245

SCHEMBL24469245

Fc1ccc(-c2ccc3c(C4CCOCC4)nnc(Cl)c3c2)nc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
P2RX7 Q99572 1/20 0.35
PIK3CB P42338 2/20 0.34
PRKDC P78527 2/20 0.34
ATM Q13315 2/20 0.34
ATR Q13535 2/20 0.34
ATRIP Q8WXE1 2/20 0.34
MTOR P42345 1/20 0.34
GRIA2 P42262 3/20 0.34
TDO2 P48775 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
MCHR1 Q99705 1/20 0.34
AOC3 Q16853 1/20 0.33
SSTR3 P32745 1/20 0.33
KCNH2 Q12809 1/20 0.33
SCD O00767 1/20 0.33
CNR2 P34972 1/20 0.33
IL2 P60568 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30660863 1.00 OPRL1 (0.35) OPRL1HDAC1HDAC2P2RX7PIK3CB
SCHEMBL24469166 0.88 HDAC1 (0.36) HDAC1HDAC2P2RX7PIK3CBPRKDC
SCHEMBL24469242 0.87 HDAC1 (0.37) OPRL1HDAC1HDAC2PIK3CBPRKDC
SCHEMBL24469184 0.78 PRKDC (0.36) P2RX7PIK3CBPRKDCATMATR
SCHEMBL24469151 0.78 GABBR2 (0.38) MCHR1MAP4K4
SCHEMBL24469168 0.77 P2RX3 (0.35) MCHR1SCDMAPK1
SCHEMBL24469169 0.76 P2RX3 (0.36) GRIA2SCD
SCHEMBL24469159 0.75 MCHR1 (0.33) GRIA2MCHR1SCD
SCHEMBL24469252 0.68 DRD2 (0.40) P2RX7PIK3CB
SCHEMBL25544649 0.66 PRKAA2 (0.34) SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12534455-B2 Phthalazine derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-01-27 US disclosed
EP-4251273-B1 PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARM SPA (IT) 2025-03-12 EP disclosed
US-20240002371-A1 PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-01-04 US disclosed
CN-116745284-A Phthalazine derivatives as P2X3 inhibitors 奇斯药制品公司 2023-09-12 CN disclosed
WO-2022112493-A1 PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12534455-B2 Phthalazine derivatives as P2X3 inhibitors P2RX3, P2RX5, P2RX7 OPRL1 222/4885HDAC1 1343/4885HDAC2 687/4885
US-20240002371-A1 PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX2 OPRL1 214/4885HDAC1 1946/4885HDAC2 728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.